Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The blood-brain barrier in migraine treatment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Monitoring chronic headache and medication-overuse headache prevalence in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Diagnostic delay of cluster headache: A cohort study from the Danish Cluster Headache Survey

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. PACAP27 induces migraine-like attacks in migraine patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Hyperpolarization through ATP-sensitive potassium channels; relevance to migraine pathology

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. CGRP in rat mesenteric artery and vein - receptor expression, CGRP presence and potential roles

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Fluorescent Analogues of Human α-Calcitonin Gene-Related Peptide with Potent Vasodilator Activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Salient aspects of the anatomy and function of the blood-barrier barrier (BBB) are reviewed in relation to migraine pathophysiology and treatment. The main function of the BBB is to limit the access of circulating substances to the neuropile. Smaller lipophilic substances have some access to the central nervous system by diffusion, whereas other substances can cross the BBB by carrier-mediated influx transport, receptor-mediated transcytosis and absorptive-mediated transcytosis. Studies of drugs relevant to migraine pathophysiology and treatment have been examined with the pressurized arteriography method. The drugs, given both luminally and abluminally, provide important notions regarding antimigraine site of action, probably abluminal to the BBB. The problems with the BBB in animal models designed to study the pathophysiology, acute treatment models and preventive treatments are discussed with special emphasize on the triptans and calcitonin gene-related peptide (CGRP). The human experimental headache model, especially the use of glycerol trinitrate (the nitric oxide model), and experiences with CGRP administrations utilize the systemic administration of the agonists with effects on other vascular beds also. We discuss how this can be related to genuine migraine attacks. Our view is that there exists no clear proof of breakdown or leakage of the BBB during migraine attacks, and that antimigraine drugs need to pass the BBB for efficacy.

OriginalsprogEngelsk
TidsskriftCephalalgia : an international journal of headache
Vol/bind28
Udgave nummer12
Sider (fra-til)1245-58
Antal sider14
ISSN0333-1024
DOI
StatusUdgivet - dec. 2008

ID: 44875207